Mister Spex SE : Growing prescription sales but Q1 results in line
>Prescription sales up +19% in Q1 but adjusted EBITDA margin in line at -3.3% - Q1 revenue was € 50.1m, i.e. growth of +6% (Q4 2022 reported a decline of -2%) with adjusted EBITDA at -€ 1.64m (margin -3.3%) vs -€ 4.6m in Q1 2022 (margin -9.7%). These figures came in very close to expectations: we had forecast, respectively, €50.2m (growth of +6.5%) and -€ 1.8m (margin -3.5%) and the company-compiled consensus was very close to our estimates. Revenue for prescription ...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.